EGFR and non-small cell lung carcinoma: Among NSCLC patients with EGFR mutations, common mutations make up 75%–80 % of cases [[4], [5], [6]], whereas uncommon mutations, including Ser768Ile (S768I), Leu861Gln (L861Q), and Gly719Xaa (G719X), constitute approximately 10 % [7].